James Wilson, MD, PhD, director of the Orphan Disease Center and Professor of Pathology and Laboratory Medicine, was quoted in a Reuters article about U.S. drugmakers facing growing resistance to the high price of cutting-edge treatments such as gene therapies, which aim to cure inherited diseases by "fixing" the single faulty gene responsible for the disorder. The article discussed new "annuity" payment models that reward drug makers for the long-term performance of their medicines. "Distributing reimbursement over many years recognizes the fact that we don't know how long these [gene therapy treatments] are going to last," he said.
Read the full Reuters article.